Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline.

What Was Tested

The paper reports a study of C-Peptide, published as a randomized controlled trial.

In a mechanistic extension of that study, the researchers evaluated peripheral blood immune cell subsets (CD4, CD8-naive, memory and activated subsets, myeloid and plasmacytoid dendritic cells, monocytes, B lymphocytes, CD4(+)CD25(high) regulatory T cells, and invariant NK T cells) by flow cytometry at baseline and 3, 6, 12, 24, and 30 months after treatment initiation to discover biomarkers of therapeutic effect.

Who Took Part

The age groups tagged for this paper are children, teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The participants were allocated by chance, so the C-Peptide group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with C-Peptide could be set against what happens without it.

What Was Measured

In a mechanistic extension of that study, the researchers evaluated peripheral blood immune cell subsets (CD4, CD8-naive, memory and activated subsets, myeloid and plasmacytoid dendritic cells, monocytes, B lymphocytes, CD4(+)CD25(high) regulatory T cells, and invariant NK T cells) by flow cytometry at baseline and 3, 6, 12, 24, and 30 months after treatment initiation to discover biomarkers of therapeutic effect.

PubMed files the paper under topics including Abatacept, C-Peptide, CD4-Positive T-Lymphocytes, Diabetes Mellitus, Type 1, Immunoconjugates, Immunologic Memory and Immunosuppressive Agents.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of C-Peptide.

The publication is from 2014 (Diabetes), a journal based in United States.

More context: the C-Peptide compound page, all human trials.